UNVERIFIEDSingle Source
STAT+: Proposed ‘preclinical obesity’ diagnosis ignites global debate among experts
Stat News|4/2/2026
O
Obesity
74 stories tracked
Executive summary being generated...
Lindy
0
Breaking
0
Unverified
37
Activity (Last 30 Days)
1
3
1
1
1
1
1
2
1
1
1
1
2026-03-052026-04-02
Top Publishers
Stat News31 stories
NYT Opinion2 stories
Google News1 stories
Reuters1 stories
Scientific American1 stories
Stories (Latest First)
UNVERIFIEDSingle Source
Eli Lilly’s obesity pill approved by FDA, setting up fierce competition with Novo Nordisk
Stat News|4/1/2026
UNVERIFIEDSingle Source
California considers seal of approval for foods that are not ultra-processed
Stat News|3/25/2026
UNVERIFIEDSingle Source
STAT+: Novo Nordisk’s high-dose Wegovy approved in the U.S.
Stat News|3/19/2026
UNVERIFIEDSingle Source
STAT+: Eli Lilly’s ‘triple-G’ drug leads to significant blood sugar, weight reductions in diabetes trial
Stat News|3/19/2026
UNVERIFIEDSingle Source
Opinion: Semaglutide is going off-patent in India. But will people who need it be able to get it?
Stat News|3/17/2026
UNVERIFIEDSingle Source
STAT+: Structure Therapeutics reports significant weight loss from mid-stage GLP-1 pill
Stat News|3/16/2026
UNVERIFIEDSingle Source
Major changes to cardiovascular guidelines suggest taking statins as young as 30
Stat News|3/13/2026
UNVERIFIEDSingle Source
STAT+: The FDA is targeting telehealth marketing of GLP-1 drugs. Who’s prescribing them?
Stat News|3/12/2026
UNVERIFIEDSingle Source
STAT+: Novo Nordisk, Hims reach deal to end bitter dispute over Wegovy sales
Stat News|3/9/2026
UNVERIFIEDSingle Source
STAT+: Novo Nordisk’s Wegovy and Ozempic shots could be made for as little as $3 a month, analysis finds
Stat News|3/6/2026
UNVERIFIEDSingle Source
How the ‘holy grail’ weight loss pill became a reality, and what comes next
Stat News|3/6/2026
UNVERIFIEDSingle Source
Weight-loss jab could be made for $3 a month, study finds
The Guardian|3/6/2026
UNVERIFIEDSingle Source
STAT+: Eli Lilly launches program for employers to subsidize cost of obesity drug outside insurance
Stat News|3/5/2026
UNVERIFIEDSingle Source
6 in 10 women will develop heart disease or stroke by 2050, heart association projects
Stat News|2/25/2026
UNVERIFIEDSingle Source
STAT+: Will Novo Nordisk’s slashing of obesity drug prices save patients’ money? It depends
Stat News|2/24/2026
UNVERIFIEDSingle Source
STAT+: Novo Nordisk’s next-gen obesity drug stumbles in comparison study
Stat News|2/23/2026
UNVERIFIEDSingle Source
Women’s heart attack risk rises even if arteries aren’t as clogged as men’s
Stat News|2/23/2026
UNVERIFIEDSingle Source
STAT+: As China’s drug industry races ahead, its GLP-1 race is accelerating too
Stat News|2/17/2026
UNVERIFIEDSingle Source
STAT+: Trump administration is urged to use a federal law to authorize generic versions of GLP-1 drugs
Stat News|2/12/2026
UNVERIFIEDSingle Source
For heart health, low-carb or low-fat diet works, as long as it’s high quality: study
Stat News|2/11/2026
UNVERIFIEDSingle Source
We tested the government’s official new AI nutrition tool: Grok
Stat News|2/10/2026
UNVERIFIEDSingle Source
Obesity increases risk of severe infections, study finds
Scientific American|2/9/2026
UNVERIFIEDSingle Source
STAT+: Lawsuit against Hims & Hers should be ‘wake-up call’ for compounders, Novo chief counsel says
Stat News|2/9/2026
UNVERIFIEDSingle Source
STAT+: Novo Nordisk sues Hims & Hers for infringing on a key Wegovy patent
Stat News|2/9/2026
UNVERIFIEDSingle Source
STAT+: Hims & Hers will stop selling compounded version of Novo’s obesity pill
Stat News|2/7/2026
UNVERIFIEDSingle Source
STAT+: HHS asks Justice Department to probe Hims & Hers over its cheaper compounded version of Wegovy
Stat News|2/7/2026
UNVERIFIEDSingle Source
STAT+: Novo Nordisk accuses Hims & Hers of ‘illegal mass compounding’ over a cheaper version of Wegovy pill
Stat News|2/5/2026
UNVERIFIEDSingle Source
A sneak peek of pharma’s Super Bowl ads: GLP-1s, tight ends, and more
Stat News|2/5/2026
UNVERIFIEDSingle Source
STAT+: Novo Nordisk sees lower sales, profits as Wegovy faces growing competition
Stat News|2/3/2026
UNVERIFIEDSingle Source
STAT+: Pfizer moves forward with its hopes for a monthly obesity drug
Stat News|2/3/2026
UNVERIFIEDSingle Source
Obesity market sales potential tightens as Novo and Lilly enter new era
Reuters|2/2/2026
UNVERIFIEDSingle Source
Triple H Weighs In On Increase In Childhood Obesity Issues - 411Mania
Google News|1/20/2026